STOCK TITAN

Generation Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference 

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Generation Bio (Nasdaq:GBIO) has announced that CEO Geoff McDonough, M.D., will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 18th at 3:00 p.m. EST. Investors can access a live webcast on the company's investor website, with a replay available for 30 days after the event.

Generation Bio specializes in genetic medicines aimed at providing sustainable, redosable treatments for both rare and common diseases. Their innovative platform utilizes a unique non-viral genetic medicine, featuring closed-ended DNA (ceDNA) and a specialized delivery system known as cell-targeted lipid nanoparticles (ctLNP). This technology is designed to enable long-lasting treatment effects from a single dose and has the potential to significantly scale up production.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare on Tuesday, April 18th at 3:00 p.m. EST. 

A live webcast of the panel will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event. 

About Generation Bio  

Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral genetic medicine platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. This approach is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific tissues and cell types, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio’s manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.  

For more information, please visit www.generationbio.com.

Investors and Media Contact 
Maren Killackey 
Generation Bio 
mkillackey@generationbio.com 
857-371-4638


FAQ

What event will Generation Bio's CEO participate in?

Generation Bio's CEO, Geoff McDonough, will participate in the 22nd Annual Needham Virtual Healthcare Conference on April 18th.

When is the fireside chat with Generation Bio's CEO scheduled?

The fireside chat is scheduled for April 18th at 3:00 p.m. EST.

How can I watch the live webcast of Generation Bio's event?

You can watch the live webcast on Generation Bio's investor website.

What technology does Generation Bio use for its genetic medicines?

Generation Bio uses a non-viral genetic medicine platform that includes closed-ended DNA (ceDNA) and cell-targeted lipid nanoparticles (ctLNP).

What is the goal of Generation Bio's genetic medicine platform?

The goal is to provide durable, redosable treatments for people living with rare and prevalent diseases.

Generation Bio Co.

NASDAQ:GBIO

GBIO Rankings

GBIO Latest News

GBIO Stock Data

145.50M
66.74M
14.52%
84.34%
2.6%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE